Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Eli Lilly and Company (LLY) recently updated its clinical study on baricitinib (LY3009104), a drug aimed at treating hospitalized pediatric patients aged 1 to less than 18 years with COVID-19. Officially titled A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19, the study sought to assess baricitinib’s safety and dosing in this young patient group.
Baricitinib, the study’s focus, is an oral drug designed to modulate immune responses and reduce inflammation, aiming to improve outcomes in pediatric COVID-19 cases.
The study was an interventional, single-group trial with no masking, intending to evaluate the treatment effects of baricitinib. It was classified as a Phase 3 trial, underlining its advanced stage in clinical research, with a primary focus on treatment outcomes.
Key dates in the study’s timeline include its initial submission on October 8, 2021, and the most recent update on December 15, 2025. However, the study has since been terminated, with limited details available regarding its conclusion.
From a market perspective, the termination of this study may slightly dampen investor sentiment around Eli Lilly’s COVID-19 initiatives, but it is unlikely to have a major impact on the company’s overall stock performance, given its diversified portfolio. However, it highlights the competitive pressures and challenges in expanding treatment options in this area, particularly in pediatric applications.
The study has been terminated. Further details and updates can be accessed on the ClinicalTrials portal.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.